Suppr超能文献

回输的活CD34(+)细胞数量可预测自体造血干细胞移植中的植入情况。

Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.

作者信息

Allan D S, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland D R, Chin-Yee I H

机构信息

Division of Hematology, University of Western Ontario, London, Ontario, Canada.

出版信息

Bone Marrow Transplant. 2002 Jun;29(12):967-72. doi: 10.1038/sj.bmt.1703575.

Abstract

Reduced CD34(+) cell viability due to cryopreservation has unknown effects on subsequent hematopoietic engraftment in autologous transplantation. Thirty-six consecutive autologous peripheral stem cell collections were analyzed for absolute viable CD34(+) cell numbers at the time of stem cell collection and prior to re-infusion. Viable CD34(+) cells were enumerated using single platform flow cytometry and the molecular exclusion dye 7-amino actinomycin D. The median number of viable CD34(+) cells was 3.6 x 10(6)/kg at the time of harvest and 2.0 x 10(6)/kg after thawing. When viable CD34(+)cells enumerated after thawing were <2.0, 2.0-5.0, or >5.0 x 10(6)/kg, the median time to platelet engraftment was 17, 12 and 10 days, respectively (P < 0.05 for comparison of the group with <2.0 x 10(6)/kg and the other two groups), and the median time to neutrophil engraftment was 13, 14 and 12 days, respectively (P = NS). A minimum of 2.0 x 10(6) CD34(+) cells/kg was harvested in 33 of 36 patients (92%) but only 19 of 36 (52%) patients met this threshold at the time of reinfusion. The reduced numbers of viable CD34(+) cells measured prior to re-infusion is associated with time to platelet engraftment and may be useful in monitoring stem cell loss during processing and identifying patients at risk of graft failure.

摘要

冷冻保存导致的CD34(+)细胞活力降低对自体移植中随后的造血植入的影响尚不清楚。对连续36例自体外周干细胞采集进行分析,以确定干细胞采集时和重新输注前绝对存活的CD34(+)细胞数量。使用单平台流式细胞术和分子排斥染料7-氨基放线菌素D对存活的CD34(+)细胞进行计数。收获时存活的CD34(+)细胞中位数为3.6×10(6)/kg,解冻后为2.0×10(6)/kg。解冻后计数的存活CD34(+)细胞<2.0、2.0 - 5.0或>5.0×10(6)/kg时,血小板植入的中位时间分别为17天、12天和10天(<2.0×10(6)/kg组与其他两组比较,P<0.05),中性粒细胞植入的中位时间分别为13天、14天和12天(P =无显著性差异)。36例患者中有33例(92%)收获的CD34(+)细胞至少为2.0×10(6)/kg,但重新输注时只有19例(52%)患者达到该阈值。重新输注前测量的存活CD34(+)细胞数量减少与血小板植入时间相关,可能有助于监测处理过程中的干细胞损失并识别有移植失败风险的患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验